In a nutshell This study reviewed the effectiveness of baricitinib (Olumiant) on the progression of structural joint damage (SJD) in patients with rheumatoid arthritis (RA). The data showed that baricitinib may significantly help slow down SJD signs found in digital imaging in patients with non-existent or insufficient...
Read More
In a nutshell This study examined the effect of sarilumab (Kevzara) compared to adalimumab (Humira) on health-related quality of life (HRQoL) based on inflammatory marker levels in patients with rheumatoid arthritis (RA). The data showed that sarilumab has a higher effect on improving aspects of HRQoL in patients...
Read More
In a nutshell This study compared the effectiveness of tocilizumab (Actemra) alone (monotherapy) to combination therapy with tocilizumab and methotrexate (Trexall) in patients with rheumatoid arthritis (RA). The study concluded that combination treatment...
Read More
In a nutshell This study investigated the relationship between the diagnosis of rheumatoid arthritis (RA) and the development of lung diseases (LDs) over five years. The study showed that the markers of RA activity were associated with the development of lung disease. Some background LDs such as interstitial lung disease...
Read More
In a nutshell This trial was carried out to examine the effectiveness of switching from upadacitinib (UPA; Rinvoq) to adalimumab (ADA; Humira) and from ADA to UPA following insufficient response in patients with rheumatoid arthritis (RA). The authors found that patients who do not respond to UPA or ADA can be...
Read More
In a nutshell This study investigated the effect of disease-modifying anti-rheumatic drugs (DMARDs) on cardiovascular disease (CVD) risk. They found that abatacept (Orencia) and tumor necrosis factor inhibitors (TNFi) were associated with decreased CVD risk. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by...
Read More
In a nutshell This study reviewed infection risk in patients treated with biologic and targeted disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by painful inflammation in the joints. RA is treated with drugs to reduce...
Read More
In a nutshell This study investigated the effect of baricitinib (Olumiant) on biomarkers in the blood, which indicate a state of joint destruction in patients with moderate to severe rheumatoid arthritis (RA). The study showed that baricitinib reduced these biomarkers and resulted in decreased RA symptoms. Some...
Read More
In a nutshell This study investigated the long-term effectiveness and safety of certolizumab pegol (Cimzia) in patients with rheumatoid arthritis (RA) from a real-world practice. They found that this medication was safe and patients had a sustained response. Some background Rheumatoid arthritis (RA) is a chronic condition. It is...
Read More
In a nutshell This study investigated the neutrophil-to-lymphocyte ratio (NLR) as an indicator of infection in patients with rheumatoid arthritis (RA) treated with tocilizumab (Actemra). They found that the NLR is an accurate indicator of infection in these patients. Some background Rheumatoid arthritis (RA) is a chronic condition. It...
Read More
In a nutshell This study investigated if biological disease-modifying anti-rheumatic drugs (bDMARDs) affect diabetes risk in patients with rheumatoid arthritis (RA). They found that bDMARD use was associated with lower rates of diabetes in these patients. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by...
Read More
In a nutshell This study investigated the effectiveness and safety of upadacitinib (Rinvoq) to abatacept (Orencia) for patients with rheumatoid arthritis (RA). The study showed that upadacitinib was more effective in lowering the disease activity score (DAS28) and in decreasing symptoms, but had more side...
Read More
